Cargando…

Comprehensive Analysis and Experimental Validation of a Novel Estrogen/Progesterone-Related Prognostic Signature for Endometrial Cancer

Estrogen and progesterone are the major determinants of the occurrence and development of endometrial cancer (EC), which is one of the most common gynecological cancers worldwide. Our purpose was to develop a novel estrogen/progesterone-related gene signature to better predict the prognosis of EC an...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Jing, Yao, Hong-Wen, Liu, Ting-Ting, Wang, Di, Shi, Jian-Hong, Yuan, Guang-Wen, Ma, Sai, Wu, Ling-Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9225250/
https://www.ncbi.nlm.nih.gov/pubmed/35743699
http://dx.doi.org/10.3390/jpm12060914
_version_ 1784733573378473984
author Yu, Jing
Yao, Hong-Wen
Liu, Ting-Ting
Wang, Di
Shi, Jian-Hong
Yuan, Guang-Wen
Ma, Sai
Wu, Ling-Ying
author_facet Yu, Jing
Yao, Hong-Wen
Liu, Ting-Ting
Wang, Di
Shi, Jian-Hong
Yuan, Guang-Wen
Ma, Sai
Wu, Ling-Ying
author_sort Yu, Jing
collection PubMed
description Estrogen and progesterone are the major determinants of the occurrence and development of endometrial cancer (EC), which is one of the most common gynecological cancers worldwide. Our purpose was to develop a novel estrogen/progesterone-related gene signature to better predict the prognosis of EC and help discover effective therapeutic strategies. We downloaded the clinical and RNA-seq data of 397 EC patients from The Cancer Genome Atlas (TCGA) database. The “limma” R package was used to screen for estrogen/progesterone-related differentially expressed genes (DEGs) between EC and normal tissues. Univariate and multivariate Cox proportional hazards regression analyses were applied to identify these DEGs that were associated with prognosis; then, a novel estrogen/progesterone-related prognostic signature comprising CDC25B, GNG3, ITIH3, PRXL2A and SDHB was established. The Kaplan–Meier (KM) survival analysis showed that the low-risk group identified by this signature had significantly longer overall survival (OS) than the high-risk group; the receiver operating characteristic (ROC) and risk distribution curves suggested this signature was an accurate predictor independent of risk factors. A nomogram incorporating the signature risk score and stage was constructed, and the calibration plot suggested it could accurately predict the survival rate. Compared with normal tissues, tumor tissues had increased mRNA levels of GNG3 and PRXL2A and a reduced mRNA level of ITIH3. The knockdown of PRXL2A and GNG3 significantly inhibited the proliferation and colony formation of Ishikawa and AN3CA cells, while the inhibition of PRXL2A expression suppressed xenograft growth. In this study, five estrogen/progesterone-related genes were identified and incorporated into a novel signature, which provided a new classification tool for improved risk assessment and potential molecular targets for EC therapies.
format Online
Article
Text
id pubmed-9225250
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-92252502022-06-24 Comprehensive Analysis and Experimental Validation of a Novel Estrogen/Progesterone-Related Prognostic Signature for Endometrial Cancer Yu, Jing Yao, Hong-Wen Liu, Ting-Ting Wang, Di Shi, Jian-Hong Yuan, Guang-Wen Ma, Sai Wu, Ling-Ying J Pers Med Article Estrogen and progesterone are the major determinants of the occurrence and development of endometrial cancer (EC), which is one of the most common gynecological cancers worldwide. Our purpose was to develop a novel estrogen/progesterone-related gene signature to better predict the prognosis of EC and help discover effective therapeutic strategies. We downloaded the clinical and RNA-seq data of 397 EC patients from The Cancer Genome Atlas (TCGA) database. The “limma” R package was used to screen for estrogen/progesterone-related differentially expressed genes (DEGs) between EC and normal tissues. Univariate and multivariate Cox proportional hazards regression analyses were applied to identify these DEGs that were associated with prognosis; then, a novel estrogen/progesterone-related prognostic signature comprising CDC25B, GNG3, ITIH3, PRXL2A and SDHB was established. The Kaplan–Meier (KM) survival analysis showed that the low-risk group identified by this signature had significantly longer overall survival (OS) than the high-risk group; the receiver operating characteristic (ROC) and risk distribution curves suggested this signature was an accurate predictor independent of risk factors. A nomogram incorporating the signature risk score and stage was constructed, and the calibration plot suggested it could accurately predict the survival rate. Compared with normal tissues, tumor tissues had increased mRNA levels of GNG3 and PRXL2A and a reduced mRNA level of ITIH3. The knockdown of PRXL2A and GNG3 significantly inhibited the proliferation and colony formation of Ishikawa and AN3CA cells, while the inhibition of PRXL2A expression suppressed xenograft growth. In this study, five estrogen/progesterone-related genes were identified and incorporated into a novel signature, which provided a new classification tool for improved risk assessment and potential molecular targets for EC therapies. MDPI 2022-05-31 /pmc/articles/PMC9225250/ /pubmed/35743699 http://dx.doi.org/10.3390/jpm12060914 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Yu, Jing
Yao, Hong-Wen
Liu, Ting-Ting
Wang, Di
Shi, Jian-Hong
Yuan, Guang-Wen
Ma, Sai
Wu, Ling-Ying
Comprehensive Analysis and Experimental Validation of a Novel Estrogen/Progesterone-Related Prognostic Signature for Endometrial Cancer
title Comprehensive Analysis and Experimental Validation of a Novel Estrogen/Progesterone-Related Prognostic Signature for Endometrial Cancer
title_full Comprehensive Analysis and Experimental Validation of a Novel Estrogen/Progesterone-Related Prognostic Signature for Endometrial Cancer
title_fullStr Comprehensive Analysis and Experimental Validation of a Novel Estrogen/Progesterone-Related Prognostic Signature for Endometrial Cancer
title_full_unstemmed Comprehensive Analysis and Experimental Validation of a Novel Estrogen/Progesterone-Related Prognostic Signature for Endometrial Cancer
title_short Comprehensive Analysis and Experimental Validation of a Novel Estrogen/Progesterone-Related Prognostic Signature for Endometrial Cancer
title_sort comprehensive analysis and experimental validation of a novel estrogen/progesterone-related prognostic signature for endometrial cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9225250/
https://www.ncbi.nlm.nih.gov/pubmed/35743699
http://dx.doi.org/10.3390/jpm12060914
work_keys_str_mv AT yujing comprehensiveanalysisandexperimentalvalidationofanovelestrogenprogesteronerelatedprognosticsignatureforendometrialcancer
AT yaohongwen comprehensiveanalysisandexperimentalvalidationofanovelestrogenprogesteronerelatedprognosticsignatureforendometrialcancer
AT liutingting comprehensiveanalysisandexperimentalvalidationofanovelestrogenprogesteronerelatedprognosticsignatureforendometrialcancer
AT wangdi comprehensiveanalysisandexperimentalvalidationofanovelestrogenprogesteronerelatedprognosticsignatureforendometrialcancer
AT shijianhong comprehensiveanalysisandexperimentalvalidationofanovelestrogenprogesteronerelatedprognosticsignatureforendometrialcancer
AT yuanguangwen comprehensiveanalysisandexperimentalvalidationofanovelestrogenprogesteronerelatedprognosticsignatureforendometrialcancer
AT masai comprehensiveanalysisandexperimentalvalidationofanovelestrogenprogesteronerelatedprognosticsignatureforendometrialcancer
AT wulingying comprehensiveanalysisandexperimentalvalidationofanovelestrogenprogesteronerelatedprognosticsignatureforendometrialcancer